SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zoetis Inc. - ZTS
PR Newswire
NEW YORK, June 7, 2024
NEW YORK, June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Zoetis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On April 12, 2024, The Wall Street Journal published an article entitled "What Killed Their Pets? Owners Blame Meds, but Vets Aren't Sure." The article reported that "[h]ealth regulators in the U.S. and Europe . . . are conducting reviews" of the Zoetis-produced drugs Librela and Solensia, respectively used to treat arthritis in dogs and cats, after "receiv[ing] thousands of reports of side effects" from pet owners.
On this news, Zoetis's stock price fell $12.75 per share, or 7.83%, to close at $149.98 per share on April 12, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
-
Improving the CAPE 10
-
4 Cheap Mining Stocks
-
CrowdStrike Selloff a Buying Opportunity After Outage
-
Markets Brief: GDP and Inflation Back in the Spotlight
-
What’s Happening in the Markets This Week
-
Can Value Stocks Really Make a Comeback?
-
When Will the Fed Start Cutting Interest Rates?
-
Do Stock Splits Really Matter?
-
Best Innovative Companies to Own: 2024 Edition
-
19 Best Healthcare Companies to Invest In
-
Truist Earnings: Repurchases Resume After Insurance Business Sale and Stronger Capital Ratios
-
After Earnings, Is Charles Schwab Stock a Buy, a Sell, or Fairly Valued?
-
Verizon Earnings: Cash Flow Looks a Touch Weak Despite Solid Wireless Growth
-
3 High Dividend Stocks to Buy Before They Become Too Expensive
-
10 Best Blue-Chip Stocks to Buy for the Long Term
-
Fifth Third Earnings: Solid Net Interest Margin, but Loan Demand Softens